DisclosuresActivity Planners This activity has been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD; Deborah Marie Stephens, DO; and Kaitlin Morrison, PhD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit. These financial relationships have been mitigated. Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing. Dr. Morrison has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/lineberger-cancer-center-grand-rounds-planning-committee. Speaker The presenter held equity in Novasenta; did consulting work for Bicara Therapeutics; BMS; Bobcat Bio; Coherus BioSciences, Inc; CorriRX Therapeutics; CureVac; FortVita Biologics; Johnson & Johnson; Merck; Merus N.V.; MeiraGTx; Nanobiotix, Novasenta, Novotech; Pfizer; and Regeneron; and received research support from Astra-Zeneca/MedImmune, Merck, and Merus N.V. These financial relationships have been mitigated by UNC CPD. |